Market brief — August 9, 2026

Friday, markets closed with the CAC 40 at 8,714.93, up 0.17%, the S&P 500 at 7,757.64, up 0.62%, the Nasdaq at 26,690.62, up 1.30%, the DAX at 26,319.45, up 0.69%, and the Euro Stoxx 50 at 6,523.86, up 0.33%, with the move still best read as a risk-on extension led by duration-sensitive growth rather than a broad macro repricing. Into Sunday’s open, the regime looks like a continuation of the same equity-led recovery: U.S. and European indices both finished firmer, while the strongest leg was in the Nasdaq, which points to renewed willingness to add to momentum and quality-growth exposure after a week in which softer inflation and rates-sensitive positioning were already doing the heavy lifting.^[5]

The key transmission channel remains rates. The equity tape is behaving as if investors are comfortable fading the recent growth scare and reloading on selective duration assets, especially in technology and healthcare, rather than rotating defensively into cash or value. That matters because the current rally does not look like indiscriminate beta chasing; it looks more like a combination of short covering and discretionary re-risking in sectors that had de-rated most when yields and policy uncertainty were pressing on multiples. The main divergence to watch is whether the equity bid can persist without a renewed easing in rate volatility; if yields reaccelerate higher, the leadership in long-duration names should narrow quickly, even if headline indices stay firm.^[5]

The Cash Scanner reinforces that reading, but with a clear tilt toward stock-specific momentum rather than a clean market-wide factor trade. The strongest signals are concentrated in U.S. healthcare and select growth: Tandem Diabetes Care (score 38) gapped up 19.1% on a 20-day breakout with volume expansion, Halozyme Therapeutics (38) jumped 20.2% on a 20-day breakout with ADX 36, and Five9 (38) rose 19.8% on a 20-day breakout with volume and ADX confirmation. That cluster says investors are rewarding earnings-sensitive or catalyst-driven names where technical compression has resolved upward. Outside healthcare, First Solar (40) added 2.4% with ADX 33, while Fastenal (38) and Agilent Technologies (35) also showed breakout or trend-confirmation signals. The mix is still overwhelmingly U.S.-centric and constructive, but it is not pure AI or megacap tech leadership; it suggests a broader hunt for growth with identifiable catalysts.[Cash Scanner]

Over the next 1–5 sessions, the dominant narrative is likely to remain whether the recent equity rebound is a genuine soft-landing re-risking or just a squeeze after overly defensive positioning. Consensus appears to expect calmer rates, better breadth, and continued support for growth equities; what is already priced in is a lot of the “no hard landing” optimism, while what remains underappreciated is how quickly the market could rotate back into defensives if incoming data or central-bank communication re-prices the path of cuts. A credible contrarian scenario is that the rally broadens beyond the Nasdaq if yields stay contained and cyclicals continue to catch up, which would validate the move as more than a duration squeeze.^[5]

The most important upcoming catalysts are U.S. inflation and activity data, which will determine whether the market keeps leaning into lower-rate positioning; any upside surprise would hit the long-duration trade first. Central-bank communication from the Fed and ECB remains the second-order driver because it can either validate or challenge the current easing narrative. Treasury supply and auction demand are the third key watchpoint, since weak demand would tighten financial conditions even without a big macro surprise. In Asia, any reopening or policy signal from China would matter mainly through industrials, commodities, and European cyclicals rather than through direct U.S. index direction.^[5]

The main risks are a renewed backup in sovereign yields, a dollar rebound that tightens global financial conditions, and a disappointment in the next data prints that forces investors to unwind the still-crowded duration trade. A fourth, more idiosyncratic risk is that the current scanner leadership proves too narrow: if names like Tandem Diabetes Care, Halozyme Therapeutics, and Five9 fail to hold their breakouts, it would argue that the move is driven more by short covering than by durable allocation.

If the 10-year yield remains contained and the Nasdaq continues to outperform the S&P 500, the current regime should extend; if yields jump and volatility picks up, the first confirmation of stress would likely show up in the most extended breakout names from the scanner before it reaches the index level. If healthcare momentum persists while First Solar and Fastenal also hold gains, that would favor a broader risk-on read; if only the largest growth names work, the move is likely still a tactical squeeze. If the CAC 40 and DAX can keep pace with the S&P 500 without a weaker euro, the European leg of the rally is becoming more self-sustaining; if not, U.S. technology remains the cleaner expression of the trade.

Bonne journée aux p&l makers.